Does Insulin Resistance Trigger Natriuretic Peptide Deficiency?

EBioMedicine

Volumn 17, Issue , 2017, Pages 11-12

  Moro, Cedric ^a  

^a Université de Toulouse   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 425; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR C; SOMATOSTATIN; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; INSULIN;

DOWN REGULATION; GLUCAGON BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HUMAN EMBRYONIC STEM CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PRIORITY JOURNAL; PROTEIN DEFICIENCY;

ATRIAL NATRIURETIC FACTOR; HUMANS; INSULIN; INSULIN RESISTANCE; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES;

EID: 85015672688     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2017.03.005     Document Type: Note

References (10)

1. Arora, P., Wu, C., Hamid, T., Arora, G., Agha, O., Allen, K., et al. Acute metabolic influences on the natriuretic peptide system in humans. J. Am. Coll. Cardiol. 67:7 (2016), 804–812.
2. Coue, M., Badin, P.M., Vila, I.K., Laurens, C., Louche, K., Marques, M.A., et al. Defective natriuretic peptide receptor signaling in skeletal muscle links obesity to type 2 diabetes. Diabetes 64:12 (2015), 4033–4045.
3. Das, S.R., Drazner, M.H., Dries, D.L., Vega, G.L., Stanek, H.G., Abdullah, S.M., et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112:14 (2005), 2163–2168.
4. Khan, A.M., Cheng, S., Magnusson, M., Larson, M.G., Newton-Cheh, C., McCabe, E.L., et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J. Clin. Endocrinol. Metab. 96:10 (2011), 3242–3249.
5. Lazo, M., Young, J.H., Brancati, F.L., Coresh, J., Whelton, S., Ndumele, C.E., et al. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes 62:9 (2013), 3189–3193.
6. Lee, Y.H., Wang, M.Y., Yu, X.X., Unger, R.H., Glucagon is the key factor in the development of diabetes. Diabetologia 59:7 (2016), 1372–1375.
7. Pivovarova, O., Gogebakan, O., Kloting, N., Sparwasser, A., Weickert, M.O., Haddad, I., et al. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity?. J. Clin. Endocrinol. Metab. 97:5 (2012), E731–E739.
8. Ryden, M., Backdahl, J., Petrus, P., Thorell, A., Gao, H., Coue, M., et al. Impaired atrial natriuretic peptide-mediated lipolysis in obesity. Int. J. Obes. 40:4 (2016), 714–720.
9. Wang, T.J., Larson, M.G., Levy, D., Benjamin, E.J., Leip, E.P., Wilson, P.W., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109:5 (2004), 594–600.
10. Zois, N.E., Terzic, D., Faerch, K., Plomgaard, P., Hansen, J.S., Rossing, P., et al. Effect of pancreatic hormones on pro-atrial natriuretic peptide in humans. EBioMedicine 17 (2017), 88–94 (this issue).